Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Item 8.01Other Events

As previously disclosed in Amendment No. 1 to its Current Report
on Form 8-K/A filed on January 5, 2017, Interpace Diagnostics
Group, Inc. (the Company) announced a registered direct public
offering of 630,000 shares of the Companys common stock, par
value $0.01 per share (the Common Stock), at a price of $6.81 per
share (the Registered Direct Offering). A copy of the legal
opinion of Pepper Hamilton LLP relating to the legality of the
issuance and sale of the shares of Common Stock in the Registered
Direct Offering is filed herewith as Exhibit 5.1.

The closing of the Registered Direct Offering is expected to take
place on January 6, 2017, subject to customary closing
conditions.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking
statements. Forward-looking statements include, but are not
limited to, statements that express the Companys intentions,
beliefs, expectations, strategies, predictions or any other
statements related to the Companys future activities, or future
events or conditions. These statements are based on current
expectations, estimates and projections about the Companys
business based, in part, on assumptions made by management. These
statements are not guarantees of future performances and involve
risks, uncertainties and assumptions that are difficult to
predict. Therefore, actual outcomes and results may differ
materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors, including
those risks discussed in the Companys Annual Report on Form 10-K
and in other documents that the Company files from time to time
with the U.S. Securities and Exchange Commission. Any
forward-looking statements speak only as of the date on which
they are made, and the Company does not undertake any obligation
to update any forward-looking statement to reflect events or
circumstances after the date of this report, except as required
by law.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) closed its last trading session down -0.37 at 6.47 with 848,980 shares trading hands.